跳轉至內容
Merck
全部照片(1)

重要文件

A9950

Sigma-Aldrich

Aniracetam

≥98%

同義詞:

1-(4-Methoxybenzoyl)-2-pyrrolidinone, Ro 13-5057

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C12H13NO3
CAS號碼:
分子量::
219.24
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

化驗

≥98%

起源

Roche

SMILES 字串

COc1ccc(cc1)C(=O)N2CCCC2=O

InChI

1S/C12H13NO3/c1-16-10-6-4-9(5-7-10)12(15)13-8-2-3-11(13)14/h4-7H,2-3,8H2,1H3

InChI 密鑰

ZXNRTKGTQJPIJK-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

應用

Aniracetam has been used in the inhibition screening assays for kinase enzyme.

生化/生理作用

Aniracetam is a piracetam analog and has low bioavailability due to rapid excretion. It enhances the cognitive thinking and is effective for treatment of sleep and behavioral disorders. Aniracetam is prescribed for anxiety and also enhances learning and memory in situations with induced damage of the brain.
Cognition enhancer (nootropic) that potentiates AMPA receptor mediated ion conductance and potentiates metabotropic glutamate receptor activity.

特點和優勢

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

未看到正確版本?

如果您需要一個特定的版本,您可以透過批號來尋找特定憑證。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

A Pittaluga et al.
Naunyn-Schmiedeberg's archives of pharmacology, 359(4), 272-279 (1999-05-27)
Aniracetam, 1-(1,3-benzodioxol-5-yl-carbonyl)piperidine (1-BCP) and cyclothiazide, three compounds considered to enhance cognition through modulation of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, were evaluated in the 'kynurenate test', a biochemical assay in which some nootropics have been shown to prevent the antagonism by kynurenic
Chrysi C Koliaki et al.
CNS neuroscience & therapeutics, 18(4), 302-312 (2011-11-11)
Dementia constitutes an increasingly prevalent cognitive disorder with serious socioeconomic implications. In the present study, we aimed to evaluate the efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors (ChEIs), in terms of several neuropsychological parameters, in a
Kazuo Nakamura
CNS drug reviews, 8(1), 70-89 (2002-06-19)
Aniracetam is a pyrrolidinone-type cognition enhancer that has been clinically used in the treatment of behavioral and psychological symptoms of dementia following stroke and in Alzheimer's disease. New discoveries in the behavioral pharmacology, biochemistry and pharmacokinetics of aniracetam provided new
Julia Vaglenova et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 33(5), 1071-1083 (2007-07-05)
Specific pharmacological treatments are currently not available to address problems resulting from fetal ethanol exposure, described as Fetal Alcohol Syndrome or Fetal Alcohol Spectrum Disorders (FASD). The present study evaluated the therapeutic effects of aniracetam against cognitive deficits in a
T H Johansen et al.
Molecular pharmacology, 48(5), 946-955 (1995-11-01)
We examined the actions of cyclothiazide, aniracetam, and 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine (GYKI-52466) on recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) and kainate receptors. Receptors expressed in Xenopus oocytes or human embryonic kidney 293 cells were characterized using voltage and patch-clamp electrophysiology. Aniracetam and cyclothiazide potentiated

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務